DOCKET NO.: I0248.70015US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Bachovchin et al.

Serial No .:

10/725,952

Confirmation No.:

3968

Filed:

December 1, 2003

For:

STIMULATION OF HEMATOPOIETIC CELLS IN VITRO

Examiner:

Not Yet Assigned

Art Unit:

1631

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450, on May 24, 2005.

Nicole Millette Hawes

MAIL STOP AMENDMENT

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

Maria A. Trevisan, Reg. No.: 48,207 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: I0248.70015US01

Date: May 24, 2005

xNDDx



DOCKET NO.: I0248.70015US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bachovchin et al.

Serial No.:

10/725,952

Confirmation No.:

3968

Filed:

December 1, 2003

For:

STIMULATION OF HEMATOPOIETIC CELLS IN VITRO

Examiner:

Not Yet Assigned

Art Unit:

1631

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 24, 2005.

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Serial No.: 10/725,952 -2 - Art Unit: 1631

Conf. No.: 3968

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

Maria A. Trevisan, Reg. No. 48,207

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: I0248.70015US01

Date: May 24, 2005

xNDDx

707) (P#0	144044	ID 04 110		APPLICATION NO.: 10/725,952		ATTY. DOC	ATTY. DOCKET NO.: I0248.70015US01		
FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE				FILING DATE: December 1, 2003 CONFIRMA			TION NO.: 3968		
			LOSURE	APPLICANT: Bachovchin et al.					
				GROTIB	GROUP ART UNIT: 1631 EXAMINER: Not Yet Assign			() F	32
Sheet	1	of	1	GROOT ART UNIT. 1051 EXAMINER: NOT YET ASSIGN			u O		
								MAY 2	7 2005
	1		* ** *		PATENT DOCUMENTS		<u> </u>	<u> </u>	
Examiner's Initials	Cite	U.	S. Patent Docume		Name of Patentee or Applicant of Ci		Date of Publication of his present		
	No.	Number		Kind Code	Document		MM-DD-YYYY		
¥				-1-					
•									
· •						· · · ·			
	т				N PATENT DOCUMENTS		D. t. C		
Examiner's Initials	Cite No.	Foreign Patent Docum			Name of Patentee or Applicant of Document		Date of Publication of	Translation	
		Office/ Country	Number	Kind Code	(not necessary)		Cited Document MM-DD-YYYY	(Y/N)	
								7	
	-		9	<u> </u>		******			
	11			<u> </u>				<u>i.</u>	
	η	T., .1., 1.			PATENT LITERATURE DOCU			Г	
Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.							ation N)
	*C129	Darmoul et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer							
	cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of								
		dipeptidyl peptidase IV mRNA levels during cell differentiation. J Biol Chem. 1992 Mar 5; 267(7):4824-33.							
	*C130	Reinhold et al., Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress							
	proliferation and modulate cytokine production of strongly CD26 expressing U937 cells.								
		Immunobiology. 1994 Dec;192(1-2):121-36.							
	-							 	
	ı			77.854				<u></u>	

EXAMINER:	DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. <u>09/812,528</u>, filed <u>March 20, 2001</u>, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).